News

The FDA orphan drug designation coincides with the positive opinion of the European Medicines Agency’s (EMA’s) Committee for Orphan Medicinal Products (COMP) regarding NiCord as a treatment for

The study is expected to commence during the first quarter of 2015. CM-24 is directed against CEACAM1, a novel immune checkpoint protein that is expressed on activated effector

Kite previously announced in March 2014 that the U.S. Food and Drug Administration (FDA) granted Orphan Drug designation for KTE-C19 for the treatment of DLBCL. Further, Kite has

TRV130 is being developed as a first-line intravenous treatment for patients experiencing moderate-to-severe acute pain. The multicenter, randomized, double-blind, placebo- and active-controlled clinical trial is designed to evaluate

As part of the deal, Gilead will pay Phenex an upfront payment plus additional payments based upon achievement of certain development milestones that may potentially be worth about

Patient enrollment is scheduled to be completed by the end of January in this trial, which is being led by the Oxford Vaccine Group, part of the University

The open-label Phase II trial will enroll 54 patients with relapsed/refractory non-Hodgkin’s lymphoma (NHL): 27 patients with diffuse large B-cell lymphoma and 27 with follicular lymphoma. Being carried

The company said that patients with advanced refractory solid tumors are being enrolled in the single-agent Phase Ia open-label dose-escalation trial. Currently, being conducted at four sites in

The trial is scheduled to start in the first quarter of 2015. It is designed to evaluate the safety and tolerability of ADXS-HER2 in patients diagnosed with metastatic